Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2391264
Max Phase: Preclinical
Molecular Formula: C27H24BrN3O4
Molecular Weight: 534.41
Molecule Type: Small molecule
Associated Items:
ID: ALA2391264
Max Phase: Preclinical
Molecular Formula: C27H24BrN3O4
Molecular Weight: 534.41
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COc1ccc(Cc2cc(-c3ccc(OC)cc3)nn(CC(=O)Nc3ccc(Br)cc3)c2=O)cc1
Standard InChI: InChI=1S/C27H24BrN3O4/c1-34-23-11-3-18(4-12-23)15-20-16-25(19-5-13-24(35-2)14-6-19)30-31(27(20)33)17-26(32)29-22-9-7-21(28)8-10-22/h3-14,16H,15,17H2,1-2H3,(H,29,32)
Standard InChI Key: ZWGMKUNSHWUUJH-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 534.41 | Molecular Weight (Monoisotopic): 533.0950 | AlogP: 4.92 | #Rotatable Bonds: 8 |
Polar Surface Area: 82.45 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 7 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 11.69 | CX Basic pKa: | CX LogP: 4.92 | CX LogD: 4.92 |
Aromatic Rings: 4 | Heavy Atoms: 35 | QED Weighted: 0.35 | Np Likeness Score: -1.26 |
1. Giovannoni MP, Schepetkin IA, Cilibrizzi A, Crocetti L, Khlebnikov AI, Dahlgren C, Graziano A, Dal Piaz V, Kirpotina LN, Zerbinati S, Vergelli C, Quinn MT.. (2013) Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists., 64 [PMID:23685570] [10.1016/j.ejmech.2013.03.066] |
Source(1):